Cytodyn Inc (CYDY)

[Blue Man]

SEC filing is specific to:

On July 2, 2020, CytoDyn Inc. (“CytoDyn” or the “Company”) signed an exclusive Distribution and Supply Agreement (the “Agreement”) with American Regent, Inc. (“American Regent”) with respect to the distribution of the Company’s leronlimab (PRO140) drug for the treatment of COVID-19 in theUnited States

Under the Agreement, the Company appointed American Regent as the sole and exclusive authorized distributor in the United States of any subcutaneousinjectable biopharmaceutical drug product labeled for treating COVID-19 that contains CytoDyn’s leronlimab (a humanized monoclonal antibody (alsoknown as PRO 140) targeting against the CCR5 receptor) as the only active pharmaceutical ingredient (the “Product”). The grant of exclusive distributionrights to American Regent does not extend to any intravenous or infusible biopharmaceutical drug product, or any other product of CytoDyn containingleronlimab that is not labeled for treating COVID-19.

What do the tea leaves reveal? Does this mean they think FDA approval for Covid is going to happen? Does this filing show the FDA Cytodyn is ready to roll? Does this help with uplisting in the future?

American Regent shall solely set the resale prices for the Product in accordance with applicable law. Pursuant to the Agreement, the Company remains responsible, at its cost, to pursue, own and maintain the applicable regulatory approvals necessary to market the Product in the United States, and for manufacturing the Product once regulatory approvals have been received

If this means what it appears, American Regent pays for the production? If so, would they bare the cost of production if they did not think it would be profitable? I realized leronlinab needs approval, but this would cut expenses at Cytodyn.

What am I not considering?